## (19) World Intellectual Property Organization

International Bureau



# 

#### (43) International Publication Date 11 August 2005 (11.08.2005)

#### PCT

### (10) International Publication Number WO 2005/073195 A2

(51) International Patent Classification<sup>7</sup>: C07K 5/02, A61P 31/14

C07D 215/00.

(21) International Application Number:

PCT/SE2005/000097

(22) International Filing Date: 28 January 2005 (28.01.2005)

(25) Filing Language:

English

(26) Publication Language:

English


(30) Priority Data:

0400199-6 30 January 2004 (30.01.2004) SE 0401288-6 19 May 2004 (19.05.2004) SE 0402562-3 22 October 2004 (22.10.2004) SE

- (71) Applicant (for all designated States except US): MEDI-VIR AB [SE/SE]; Lunastigen 7, S-141 44 Huddinge (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ROSENQUIST, Asa [SE/SE]; c/o Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). THORSTENSSON, Fredrik [SE/SE];

Hans [SE/SE]; c/o Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE).

- (74) Agent: AWAPATENT AB; Box 45086, S-104 30 Stockholm (SE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).



pounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.